同位素 ›› 2019, Vol. 32 ›› Issue (3): 178-185.DOI: 10.7538/tws.2019.32.03.0178

• 创刊30周年纪念专刊 • 上一篇    下一篇

中国放射性药物制备的现状及展望

张锦明1;杜进2   

  1. 1.解放军总医院 核医学科,北京100853; 2.中国同辐股份有限公司,北京100045
  • 出版日期:2019-06-20 发布日期:2019-06-13

Preparation of Radiopharmaceuticals in China: Current Status and Prospects

ZHANG Jinming1;DU Jin2   

  1. 1.Department of Nuclear Medicine, The PLA General Hospital, Beijing 100853, China; 2.China Isotope & Radiation Corporation, Beijing 100045, China
  • Online:2019-06-20 Published:2019-06-13

摘要:

介绍我国放射性药物制备发展的初级、起步和快速发展三个阶段,从企业和医院的放射性药物生产和制备两个方面介绍目前放射性药物制备的现况,针对存在的问题,提出措施和建议。基于PSMA的放射性药物用于肿瘤诊断和治疗有可能成为热点,而中枢神经退行性疾病中,Tau 蛋白显像剂的临床应用价值则更大。

关键词: 放射性药物, 诊断, 治疗, 显像剂

Abstract:

The histrotry of radiopharmaceuticals development in China could be classified into three stages: the begining stage, the settelement stage and the rapid development stage. The current status of the preparation of radiopharmaceuticals from enterprises and hospitals was reviewed, and the measures and suggestions were put to resolve the problem which occurred in recent radiopharmaceuticals development. The research of development of PSMA based diagnostic and therapeutic radiopharmaceuticals would be hot spot. The Tau protein imaging will be more valuable in degenerative diseases of CNS.

Key words: radiopharmaceuticals, diagnose, therapy, imaging agent